U.S., April 1 -- ClinicalTrials.gov registry received information related to the study (NCT07504263) titled 'Phase 1/2a Study of RP-001 in Participants With Advanced Malignancies' on March 21.
Brief Summary: Phase 1/2a Study of RP-001 in participants with Advanced Malignancies
Study Start Date: April 23
Study Type: INTERVENTIONAL
Condition:
Advanced Malignancies
Oncology
Colorectal Cancer
Pancreatic Cancer
Cancer
Intervention:
DRUG: RP-001
A new class of Taxane.
Recruitment Status: NOT_YET_RECRUITING
Sponsor: Recurv Pharma Inc
Disclaimer: Curated by HT Syndication....